Welcome to our dedicated page for Jounce Therapeutics news (Ticker: JNCE), a resource for investors and traders seeking the latest updates and insights on Jounce Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jounce Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jounce Therapeutics's position in the market.
Jounce Therapeutics reported its Q1 2020 results, ending with $148.6 million in cash. The COVID-19 pandemic impacted the enrollment of the EMERGE Phase 2 trial and initiation of the SELECT trial, causing delays of 2 to 3 months. Interim analysis of the EMERGE trial is now expected in early 2021. Jounce announced CCR8 as the JTX-1811 target, with preclinical data to be presented at AACR 2020 in June. Operating expenses are projected to be $80 to $95 million for the year, but the company expects sufficient cash to meet its needs through 2021.
